Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China：Correlation Between Recurrence and Drug Withdrawl

NCT03358212 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03358212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03358212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China：Correlation Between Recurrence and Drug Withdrawl
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2018
Completion date
June 1, 2021
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell tumor of bone